<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574170</url>
  </required_header>
  <id_info>
    <org_study_id>11 SEIN 07</org_study_id>
    <nct_id>NCT01574170</nct_id>
  </id_info>
  <brief_title>Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival</brief_title>
  <acronym>METAL3</acronym>
  <official_title>Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomedical study of interventional type. The trial will include 270 patients (180
      patients in the first cohort and 90 patients in a second cohort) over a period of 3 years + 2
      years of follow up.

      This prospective study will be conduct in patients who will receive a third line chemotherapy
      for metastatic breast cancer.

      The main objective of the study (first cohort) is to identify patients who benefit from a
      third line treatment in terms of overall survival with a score established from clinical,
      histological, but also biological &quot;classic&quot; and &quot;innovative&quot; (account of circulating tumor
      cells) criteria, all of these criteria must be measurable before the introduction of the 3rd
      line.

      This score will then be validated on the 2nd cohort.

      There will be no interruption of inclusions between first and second cohort of patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2012</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival defined as the time from patient inclusion to the date of death or date of last follow-up news (censured data)</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to progression, defined as the time from patient inclusion to the date of the first documented tumor progression</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the EORTC QLQ-C15-PAL Questionnaire</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction regarding therapeutic decisions at inclusion using a specific questionnaire developed by Llewellyn-Thomas</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologists satisfaction regarding the management and communication with the patient will be studied at baseline and at the time or progression using the Likert ordinal scale</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regret or not of the patient to have followed a 3rd line of chemotherapy will be recorded at the end of the treatment using the &quot;Decision regret scale&quot; Questionnaire, established by A. O'Connor</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluated according to the classification of NCI CTCAE (Common Terminology Criteria for Adverse Events) V4.0</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Metastatic Breast Cancer Starting a Third Line Chemotherapy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Construction of a prognostic score (non-drug intervention types)</intervention_name>
    <description>Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women of more than 18 years old

          2. WHO 0-4

          3. Metastatic breast cancer

          4. Progression after two lines of chemotherapy with treatment decision by investigator to
             start a third-line chemotherapy

          5. Evaluable disease

          6. Histology: breast carcinoma whatever the histological type, grade, hormone receptor
             expression and HER-2

          7. Patient able to complete the EORTC PAL 15 Questionnaire

          8. Patient member in a national insurance scheme

          9. Informed consent obtained and signed by the patient

        Exclusion Criteria:

          1. History of other (s) cancer (s) potentially metastatic (s)

          2. Woman participating in a third line chemotherapy clinical trial

          3. Pregnant women or nursing mothers can not participate in the study

          4. Patient under legal guardianship

          5. Patient unable to undergo medical test for various reasons including social or
             psychological reasons.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence MD DALENC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Md DALENC</last_name>
    <phone>+33 5.61.42.41.28</phone>
    <email>Dalenc.florence@claudiusregaud.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>C.M.C.O. Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann BERGE, Md.</last_name>
      <phone>05 63 77 77 57</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Yann BERGE, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick SOULIE, PhD</last_name>
      <phone>+ 33 2 41 35 27 34</phone>
      <email>p.soulié@unimedia.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick SOULIE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie ABADIE LACOURTOISIE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémy DELVA, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Joseph CAPITAIN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe MAILLART, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa CURTIT, Md.</last_name>
      <phone>03 81 66 92 12</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Elsa CURTIT, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>26609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène SIMON, PhD</last_name>
      <phone>+33 2 98 22 33 95</phone>
      <email>helene.simon@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène SIMON, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte LUCAS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jean Rougier</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia LEVASSEUR, Md.</last_name>
      <phone>05 65 20 50 50</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Nadia LEVASSEUR, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Castres-Mazamet</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hazem Georges HASWANI, Md.</last_name>
    </contact>
    <investigator>
      <last_name>Corinne SARDA, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane DARUT-JOUVE, Md.</last_name>
      <phone>03 80 67 30 10</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Ariane DARUT-JOUVE, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DESMOULINS, PhD</last_name>
      <phone>+33 3 45 34 80 51</phone>
      <email>idesmoulins@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle DESMOULINS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Séverine GUIU, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno COUDERT, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise MAYER, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Union</name>
      <address>
        <city>L'Union</city>
        <zip>31240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe PERRIN, Md.</last_name>
      <phone>+33 2 99 25 32 80</phone>
    </contact>
    <investigator>
      <last_name>Christophe PERRIN, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo REYES-ORTEGA, Md.</last_name>
      <phone>05 65 55 22 10</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Guillermo REYES-ORTEGA, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PETIT, Pr.</last_name>
      <phone>03 88 25 24 24</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Thierry PETIT, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de l'Ormeau</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie FICHET, Md.</last_name>
      <phone>05 62 56 40 40</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Virginie FICHET, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DALENC, PhD</last_name>
      <phone>+33 5.61.42.41.28</phone>
      <email>Dalenc.florence@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence GLADIEFF, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis LACAZE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri ROCHE, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence DALENC, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Jean du Languedoc</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne SUC, Md.</last_name>
      <phone>05 61 54 90 14</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Etienne SUC, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel UWER, Md.</last_name>
      <phone>03 83 59 84 72</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Lionel UWER, Md.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer,</keyword>
  <keyword>Third line metastatic</keyword>
  <keyword>Chemotherapy,</keyword>
  <keyword>Overall survival,</keyword>
  <keyword>Quality of life.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

